Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Terbinafine can, in rare cases, injure the liver, causing hepatitis, cholestatic liver damage, and in very rare instances liver failure, even in people with no history of liver disease. Warning signs to watch for include yellowing of the skin or eyes, dark urine, pale stools, persistent nausea or vomiting, loss of appetite, upper right abdominal pain, unexplained fatigue, and itching, most often appearing within the first four to six weeks of treatment. Baseline liver blood tests, existing liver conditions, alcohol use, and interactions with other medications all change your level of risk, and there are important details on when to stop the drug and call a clinician below.
Because liver symptoms overlap with far more common and harmless causes, the fastest way to tell whether your symptoms need urgent attention is to check them systematically rather than guess. Take a free, instant, online symptom check to better understand what may be going on and to see what steps to take next.
Last reviewed for medical accuracy: 09/12/2026
Can Terbinafine Damage My Liver and What Warning Signs Should I Watch For?
Terbinafine is an antifungal medication commonly prescribed as pills or topical creams to treat nail fungus, ringworm, athlete’s foot and other skin infections. It works by blocking an enzyme that fungi need to grow, helping clear stubborn infections. While terbinafine is generally safe for most people, on rare occasions it can affect liver function. Understanding the risks, watching for early warning signs and knowing when to seek help can keep you safe without causing unnecessary worry.
• Terbinafine is processed (metabolized) by the liver.
• In most people, the liver handles terbinafine easily and breaks it down into harmless substances.
• In rare cases—estimated at about 1 in 50,000 to 1 in 120,000 users—terbinafine can trigger liver inflammation (hepatitis) or more serious liver injury.
• The exact reason is unclear. It may involve an unusual immune or toxic reaction to the drug or its byproducts.
Certain factors may raise your chance of liver problems while taking terbinafine:
If any of these apply to you, your doctor may order blood tests before you start terbinafine and schedule follow-up checks.
• Most cases of liver injury appear within the first 4 to 6 weeks of treatment.
• Rarely, changes can occur after longer courses of therapy (for example, a 12-week nail fungus regimen).
• Once terbinafine is stopped, mild liver enzyme elevations often improve within days to weeks. Severe cases can require medical treatment or even hospitalization.
Pay attention to your body while taking terbinafine. Early detection of liver stress helps prevent more serious damage. Contact your healthcare provider if you notice:
• Persistent tiredness or weakness that doesn’t improve with rest
• Loss of appetite, nausea or vomiting
• Abdominal pain, especially on the right side (where your liver sits)
• Dark urine (tea-colored)
• Pale stools (clay-colored)
• Itchy skin without a rash
• Yellowing of the skin or eyes (jaundice)
• Unusual bleeding or bruising
If you experience any of these warning signs, stop the medication and speak to a doctor right away.
Not sure whether to call your doctor now or wait until a scheduled visit? You might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help guide your next steps. It’s quick, private and based on clinical guidelines.
Before you start terbinafine, discuss these steps with your healthcare provider:
During therapy:
For most people, terbinafine successfully clears fungal infections with minimal side effects. The risk of serious liver injury is very low when you:
Discuss with your doctor whether terbinafine is the right choice for you, especially if you have any risk factors.
If you develop any of these more severe symptoms, call emergency services or get to an emergency department right away:
These may signal acute liver failure or other serious complications.
Terbinafine remains a highly effective treatment for fungal infections. While liver injury is rare, being informed and watching for warning signs ensures that you can use the medication safely. Remember:
For additional guidance about your symptoms, try a free, online symptom check, using the doctor approved Ubie Symptom Checker. And always reach out to your healthcare provider about anything life-threatening or serious. Your health and safety come first.
(References)
* van 't Wout JW, Herrmann WA, de Vries RA, Stricker BH. Terbinafine-associated hepatic injury. J Hepatol. 1994 Jul;21(1):115-7. doi: 10.1016/s0168-8278(94)80146-0. PMID: 7963410.
* Ajit C, Suvannasankha A, Zaeri N, Munoz SJ. Terbinafine-associated hepatotoxicity. Am J Med Sci. 2003 May;325(5):292-5. doi: 10.1097/00000441-200305000-00008. PMID: 12792250.
* Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf. 2017 Feb;16(2):149-165. doi: 10.1080/14740338.2017.1270264. Epub 2016 Dec 16. PMID: 27927037.
* Liu D, Wong CC, Fu L, Chen H, Zhao L, Li C, Zhou Y, Zhang Y, Xu W, Yang Y, Wu B, Cheng G, Lai PB, Wong N, Sung JJY, Yu J. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med. 2018 Apr 18;10(437):eaap9840. doi: 10.1126/scitranslmed.aap9840. PMID: 29669855.
* Kaushal M, Tolani P, Kumar N, Sharma S. Terbinafine-induced liver injury. Natl Med J India. 2017 Nov-Dec;30(6):321-323. doi: 10.4103/0970-258X.239071. PMID: 30117442.
* Mejías Manzano MLÁ, Giráldez Gallego Á, Ontanilla Clavijo G, Sousa Martín JM. Terbinafine-induced hepatotoxicity. Gastroenterol Hepatol. 2019 Jun-Jul;42(6):394-395. doi: 10.1016/j.gastrohep.2018.05.022. Epub 2018 Jul 6. PMID: 31167724.
* Hoofnagle JH. Terbinafine. 2012. PMID: 31643929.
* Gupta AK, Stec N, Summerbell RC, Shear NH, Piguet V, Tosti A, Piraccini BM. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1972-1990. doi: 10.1111/jdv.16394. Epub 2020 Jun 5. PMID: 32239567.
* Jilani M, Zaidi S, Cazares Parson M, Brockman MJ, Hakim N, Edwards BP. Terbinafine-Induced Liver Injury: A Case Report. Cureus. 2023 Dec;15(12):e50749. doi: 10.7759/cureus.50749. Epub 2023 Dec 18. PMID: 38239534; PMCID: PMC10794162.
* Wen J, Zhang X, Wong CC, Zhang Y, Pan Y, Zhou Y, Cheung AH, Liu Y, Ji F, Kang X, Liu D, Yu J. Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma. Gut. 2024 Nov 11;73(12):2023-2036. doi: 10.1136/gutjnl-2023-331117. Epub 2024 Nov 11. PMID: 38744443; PMCID: PMC11671884.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.